Pfizer Builds Biotechnology Facility in China
The facility will be built in approximately 18 months using GE Healthcare’s KUBio modular facility solution.
On June 27, 2016 Pfizer announced its plans to invest approximately $350 million in the development of a biotechnology facility in Hangzhou Economic Development Area, China. This is Pfizer’s third biotechnology center, and the company’s first center in Asia, Pfizer said in a press announcement.
This new facility, called a Global Biotechnology Center, will include GE Healthcare’s single-use technology the KUBio modular facility, which decreases facility build time to 18 months. GE Healthcare's KUBio solution offering includes bioprocessing equipment and building and project coordination services. JHL Biotech also recently installed a KUBio facility in Wuhan, China for the manufacture of biosimilars and monoclonal antibodies.
Pfizer’s biotechnology facility is expected to be completed in 2018, and will house Pfizer China’s Biosimilars and Biologics Quality, Technical Service, Logistics and Engineering divisions in addition to commercial manufacturing. The facility will also serve as a process development and clinical supply site, and will create 150 jobs in the area.
Source: Pfizer
EMA Recommends Imfinzi-Based Perioperative Regimen for Treating Resectable NSCLC
March 10th 2025The committee’s recommendation is based on results from a Phase III trial in which Imfinzi demonstrated a reduced risk of recurrence, progression, or death by 32% compared to neoadjuvant chemotherapy alone.
International Women’s Day 2025: A Promising Future for Gender Diversity in Pharma
March 8th 2025In an interview with BioPharm International®, Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
